Nachrichten zur Bristol-Myers Squibb Co. Aktie

Bristol Myers Squibb Invests $35 Million in Immatics

Bristol Myers Squibb Invests $35 Million in Immatics...…

Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb

Tuebingen, Germany and Houston, TX, July 24, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in…

Bristol Myers nabs EU endorsement for Opdivo in melanoma

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers Gets CHMP Backing for Opdivo in Expanded Melanoma Use >BMY

Bristol Myers Gets CHMP Backing for Opdivo in Expanded Melanoma Use >BMY...…

Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know

Bristol Myers Squibb (BMY) closed the most recent trading day at $62.06, moving +0.1% from the previous trading session....…

Johnson & Johnson sues Biden administration over Medicare drug price negotiations

Merck, Bristol Myers Squibb, the U.S. Chamber of Commerce and PhRMA filed separate lawsuits against the provision last month....…

HSBC bullish on Roche, Lonza; bearish on Bristol-Myers, GSK, Moderna

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers (BMY) Reports Positive Data From Urothelial Cancer Study

Bristol Myers (BMY) meets its dual primary endpoint in the late-stage expansion study of Opdivo for the treatment of unresectable…

Tuesday Top Analysts Upgrades and Downgrades: Advance Auto Parts, Blackrock, Bristol-Myers Squibb Company, CAVA Group, Charles Schwab, First Solar, Fox Corporation, Invesco, Northern Trust, Shockwave Medical, Tesla and More

These are the top analyst upgrades, downgrades, and initiations seen before markets opened on Tuesday, July 11, 2023....…

Evotecs strategische Allianzen: Ein Sprung nach vorn in der Biotechnologie - Aktienanalyse

Frankfurt (www.aktiencheck.de) - Evotec-Aktienanalyse von FMR Research: Dr. Mohamad Vaseghi, Aktienanalyst von FMR Research, empfiehlt in einer aktuellen Aktienanalyse die Aktie…

Bristol Myers succeeds in Phase 3 trial for Opdivo in bladder cancer

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ROUNDUP/Vertiefte Neurologie-Partnerschaft mit BMS - Evotec erhält Millionen

HAMBURG (dpa-AFX) - Die Zusammenarbeit mit dem US-Pharmakonzern Bristol Myers Squibb (BMS) (Bristol-Myers Squibb) bei neurodegenerativen Erkrankungen zahlt sich für…

Bristol Myers inks licensing pact under Evotec neuroscience deal

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Evotec: Zusammenarbeit mit BMS zahlt sich erneut aus - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Evotec-Aktienanalyse von "Der Aktionär": Marion Schlegel vom Anlegermagazin "Der Aktionär" nimmt die Aktie der Evotec SE (ISIN: DE0005664809,…

Evotec: Bristol-Myers-Deal zahlt sich aus – Aktie zieht an

Die Zusammenarbeit mit dem US-Pharmakonzern Bristol Myers Squibb (BMS) zahlt sich für den Wirkstoffforscher Evotec erneut aus. BMS habe von…

Evotec und Bristol Myers Squibb vertiefen Neurologie-Partnerschaft

HAMBURG (dpa-AFX) - Die Zusammenarbeit mit dem US-Pharmakonzern Bristol Myers Squibb (BMS) zahlt sich für den Wirkstoffforscher Evotec (EVOTEC SE)…

Evotec Get $40 Mln Payment As Bristol Myers Enters Global Licence Agreement

NEW YORK CITY (dpa-AFX) - Evotec SE (EVO) announced that Bristol Myers Squibb Company (BMY) has exercised its option to…

Evotec SE: Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership

EVOTEC AND BRISTOL MYERS SQUIBB ENTER EXCLUSIVE GLOBAL LICENCE AGREEMENT FOR SELECTED PROGRAMMES DEVELOPED AND PROGRESSED IN THE COLLABORATIONSELECTED PROGRAMMES…

Evotec und Bristol Myers Squibb vertiefen Neurologie-Partnerschaft

FRANKFURT (Dow Jones)--Evotec und Bristol Myers Squibb vertiefen ihre Neurologie-Partnerschaft. Wie Evotec mitteilte, wird Bristol Myers Squibb von seiner Option…

Corporate News: Evotec SE

Evotec und Bristol Myers Squibb gehen Lizenzvereinbarung innerhalb ihrer Neurologie-Partnerschaft ein...…

XFRA : DIVIDEND/INTEREST INFORMATION - 06.07.2023 - US1101221083

Das Instrument BRM US1101221083 BRISTOL-MYERS SQUIBBDL-10 EQUITY wird ex Dividende/Zinsen gehandelt am 06.07.2023 The instrument BRM US1101221083 BRISTOL-MYERS SQUIBBDL-10 EQUITY has…

Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?

Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients…

XETR : DIVIDEND/INTEREST INFORMATION - 06.07.2023 - US1101221083

Das Instrument BRM US1101221083 BRISTOL-MYERS SQUIBBDL-10 EQUITY wird cum Dividende/Zinsen gehandelt am 05.07.2023 und ex Dividende/Zinsen am 06.07.2023 The instrument BRM…

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

Bristol Myers Squibb (BMY) closed the most recent trading day at $63.95, moving -0.08% from the previous trading session....…

Big Pharma Vs. Washington - An Opportunity To Buy Pfizer

As I mentioned on my last Blog Post, blood clot drug Eliquis, sold by both Bristol Myers and Pfizer, is…

Bristol Myers Squibb Enters Oversold Territory

making Bristol Myers Squibb even more interesting is the fact that in trading on Wednesday, shares of BMY entered into…

Bristol Myers (BMY) Heart Drug Camzyos Wins EC Approval

Bristol Myers (BMY) receives EC approval for Camzyos for treating symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic…

Bristol-Myers Squibb wins EC approval of Camzyos for cardiomyopathy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers Camzyos Gets European Commission Approval

NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) Monday announced that the European Commission (EC) has approved Camzyos for…

Big Pharma Vs. Washington—An Opportunity To Buy Bristol Myers

After all, news broke on Friday that Bristol Myers Squibb has sued Uncle Sam over a Medicare price renegotiation program…

Pharmaceutical trade group sues Biden administration over Medicare drug price negotiations

PhRMAs lawsuit is the fourth legal challenge to the law after separate suits from Merck, Bristol Myers Squibb and the…

Bristol Myers reportedly sues over new Medicare drug pricing program

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers (BMY) Announces CAR T Cell Therapy Breyanzi Data

Bristol Myers (BMY) CAR T cell therapy Breyanzi (lisocabtagene maraleucel) shows deep and durable responses in relapsed or refractory follicular…

Bristol Myers sues US government over Medicare drug price negotiation plan

...By Patrick Wingrove (Reuters) - Bristol Myers Squibb Co......…

UPDATE 1-Bristol Myers sues US government over Medicare drug price negotiation plan

... Wingrove June 16 (Reuters) - Bristol Myers Squibb Co on Friday sued......…

Bristol Myers Squibb sues federal government over Medicare drug negotiations: report

Bristol Myers Squibb Co. BMY is suing the federal government over Medicare’s drug price negotiation program, CNBC reported late Friday.…

Bristol Myers Squibb sues Biden administration over Medicare drug negotiations

Um den gesamten Artikel unter cnbc.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers (BMY) Gets FDA Nod for Data Addition to Camzyos

Bristol Myers (BMY) receives FDA approval for additional data to be added to the label of the heart drug Camzyos....…

Bristol-Myers Squibb Company  declares $0.57 dividend

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers Squibb (BMY) Flat As Market Gains: What You Should Know

In the latest trading session, Bristol Myers Squibb (BMY) closed at $64.76, marking no change from the previous day....…

This Drug Candidate Could Be a Winner for Bristol Myers

Bristol Myers lung cancer drug candidate could be just months away from U.S. Food and Drug Administration approval....…

Bristol-Myers gets FDA approval for Devens cell therapy manufacturing facility

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers Squibb Facility Gets Commercial Production Approval From FDA

Bristol Myers Squibb Facility Gets Commercial Production Approval From FDA...…

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

Bristol Myers Squibb (BMY) closed at $65.16 in the latest trading session, marking a -0.49% move from the prior day....…

Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study

Bristol Myers (BMY) reports encouraging four-year clinical efficacy results from its lung cancer study upon treatment with the combination immunotherapy…

OBI Pharma gibt Wechsel in der Geschäftsführung bekannt – Dr. Heidi Wang als Chief Executive Officer ernannt

Dr. Wang wurde vom Verwaltungsrat von OBI Pharma als Chief Executive Officer ernannt, um OBI Pharma mit der Vision zu…

The Zacks Analyst Blog Highlights NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance

NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance are included in this Analyst Blog....…

OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. Appointed as Chief Executive Officer

Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a…

Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know

Bristol Myers Squibb (BMY) closed the most recent trading day at $64.68, moving +0.37% from the previous trading session....…

Top Analyst Reports for NVIDIA, Bristol-Myers Squibb & ICICI Bank

Todays Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Bristol-Myers Squibb Company (BMY) and…